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Brucella spp.We report here that a bacterial protease inhibitor from Brucella spp. calledU-Omp19 behaves as an ideal constituent
for a vaccine formulation against infectious diseases.When co-administered orallywith an antigen (Ag), U-Omp19:
i) can bypass the harsh environment of the gastrointestinal tract by inhibiting stomach and intestine proteases and
consequently increases the half-life of the co-administered Ag at immune inductive sites: Peyer's patches and
mesenteric lymph nodes while ii) it induces the recruitment and activation of antigen presenting cells (APCs)
and increases the amount of intracellular Ag insideAPCs. Therefore,mucosal aswell as systemicAg-speciﬁc immune
responses, antibodies, Th1, Th17 and CD8+ T cells are enhanced when U-Omp19 is co-administered with the Ag
orally. Finally, this bacterial protease inhibitor in anoral vaccine formulation confersmucosal protection and reduces
parasite loads after oral challenge with virulent Toxoplasma gondii.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Among different mucosal routes, oral delivery is the natural choice
not only for drugs, but also for vaccines, by virtue of its ease of adminis-
tration and cost. Although oral delivery of vaccines has been the Holyminotransferase; APCs, antigen
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taro).
. This is an open access article underGrail for generations of vaccinologists [1], oral vaccination has been his-
torically thought to be largely ineffective at providing effective mucosal
and/or systemic immunity. This is mainly due to the fact that antigens
(Ags) undergo proteolytic degradation in the stomach and intestine.
Another barrier that would be bypassed by inducing an appropriate
inﬂammatory response is the immune tolerance resulting from Ag
feeding [2]. Consequently, to reliably immunize orally with peptide- or
protein-based vaccines, Ags must be protected, uptake enhanced and
the immune tolerance properly controlled.
Induction of immune responses following mucosal immuni-
zation with non-live vaccines is usually dependent upon the co-
administration of appropriate adjuvants that can initiate and support
the transition from innate to adaptive immunity [3]. Currently, to induce
mucosal adaptive immune responses — in mice — two powerful adju-
vants are used: cholera toxin (CT) from Vibrio cholera and labile entero-
toxin (LT) from Escherichia coli [4]. In humans, however, they are
responsible for the cholera and “Travelers diarrhea” and therefore can-
not be used. In attempt to avoid the enterotoxic effects caused mainly
by the A subunit of the cholera toxin, subunit B (CTB) was expressedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mutant LT (dmLT), with reduced enterotoxicity was developed and
shown to increase immune responses [6]. Different strategies to increase
Ag delivery like antigen targeting to M cells, nanoparticle-releasing vac-
cines at the colon, etc. for enhancing the efﬁcacy of mucosal vaccines
have been and are currently being investigated [7–10]. Meanwhile dif-
ferent new approaches need to be explored to develop novel oral adju-
vants and delivery systems [11], especially there is a need of those that
can induce T helper (Th)1 and CD8+ T cell responses that can prevent in-
fectious diseases related to intracellular pathogens.
In our laboratory we have beenworking on the use of a Brucella spp.
protein devoid of its lipid moiety called U-Omp19 (Unlipidated Outer
membrane protein 19) as an antigen for a vaccine against brucellosis.
This protein is soluble and easy to express and purify at high scales
[12,13]. Oral immunization with U-Omp19 produced either in E. coli or
in plants without adjuvants conferred signiﬁcant protection against
oral B. abortus infection and induced a mixed Th1-17 immune response
independent of TLR4. U-Omp19 also induced the maturation of murine
dendritic cells (DCs) in vivo [14].
Of note, BLAST, Pfam and MEROPS sequence analysis report that
U-Omp19 has sequence identity with other bacterial protease inhibi-
tors, particularly with those of the protease inhibitor family inh from
Erwinia chrysanthemi (family I38) [15,16]. This family of proteins
would interact with speciﬁc proteases released by plant, insect and
animal pathogens [15,17]. Thus, we hypothesize that U-Omp19 would
inhibit protease activity at mucosal tissues and would increase the
half-life of the co-administered Ag thus increasing its immunogenicity.
In this work we demonstrate that this bacterial protease inhibitor
protects antigens delivered in oral vaccines from digestion while
triggers speciﬁc mucosal immune responses. To our knowledge there
are no reports in the literature describing the use of bacterial protease
inhibitors in oral vaccine formulations. Therefore, this is an unconven-
tional bacterial molecular pattern never explored before.
2. Materials and methods
2.1. Ethics statement
All experimental protocols of this study were conducted in strict ac-
cordancewith international ethical standards for animal experimentation
(Helsinki Declaration and its amendments, Amsterdam Protocol of wel-
fare and animal protection and National Institutes of Health, USA NIH,
guidelines: Guide for the Care and Use of Laboratory Animals). The proto-
cols of this study were approved by the Institutional Committee for the
Care and Use of Laboratory Animals (CICUAL) from the University of
Buenos Aires (Permit Number: 2079) and CICUAE from University of
San Martin (Permit Number: 052,014), Buenos Aires, Argentina.
2.2. Animals
Eight week old female BALB/c, C57BL/6 or C3H/HeN mice were
purchased from University of La Plata (La Plata, Argentina) or from
University of San Martín (UNSAM) and housed in the animal resources
facility of University of Buenos Aires (UBA) or UNSAM (Buenos Aires,
Argentina). Animals were devoid of food but with free access to water
2 h previous and 2 h after any administration/immunization.
2.3. Ags and adjuvants
Chicken egg OVA grade V (Sigma)was used as amodel Ag. Recombi-
nant unlipidated (U)-Omp19was obtained as previously described [13].
LPS contamination from U-Omp19 was adsorbed with Sepharose-
polymyxin B (Sigma). Endotoxin determination was performed with
Limulus amoebocyte chromogenic assay (LONZA). All U-Omp19 prepa-
rations used contained b0.1 endotoxin units per mg of protein. CT and
aprotinin were purchased from Sigma.2.4. Determination of protease inhibitor activity in vitro and in vivo
Protease activity was determined using a casein ﬂuorimetric kit
(EnzChek, Invitrogen). This kit has casein-BODIPY-FL, whose ﬂuores-
cence is quenched. Protease-catalyzed hydrolysis relieves this
quenching, yielding bright green ﬂuorescent peptides. The increase in
ﬂuorescence emission is proportional to casein digestion and protease
activity. Pepsin (0.483 μM, Sigma), pancreatic Elastase (0.965 μM,
Sigma), Trypsin (0.965 μM, Sigma), α-Chymotrypsin (0.965 μM,
Sigma), Carboxypeptidase A (0.160 μM, Sigma) and B (0.065 μM,
Sigma) were incubated with U-Omp19 at different molar ratios
protease:U-Omp19 (1:1, 1:5, 1:10 and 1:50 — only for pepsin). As pos-
itive control a mammalian protease inhibitor cocktail was used. Bovine
serum albumin (BSA) and U-Omp16 – a Brucella spp. protein with a
similar molecular weight to U-Omp19 and expressed and puriﬁed
in the same way – were used as negative controls. Each reaction
mixwas incubated at room temperature (RT) for 1 h and then substrate
(casein-BODIPY-FL, 1 μg/ml) was added. Fluorescence was measured
with a ﬂuorescence plate reader (FilterMaxF5 Molecular devices).
To study pH stability of the inhibitory activity of U-Omp19, U-
Omp19 was pre-incubated at RT for 1 h at different pH (2, 5, 7.5 and
8) buffers containing 10 mM sodium phosphate and 50 mM NaCl and
then adjusted to the optimum pH for α-Chymotrypsin (pH = 7.8).
Microcon 3 (Biopore, Germany) was then used to exchange buffers. Re-
sidual inhibitor activity was assessed using casein-BODIPY (1 μg/ml)
and α-chymotrypsin (0.965 μM) as model protease in a molar ratio
protease: U-Omp19 of 1:10. Thermal stability of the inhibitory activity
of U-Omp19 was assessed by incubating different tubes containing
U-Omp19 at different temperatures (25–100 °C) for 1 h and subse-
quently adjusting them at RT. Residual inhibitor activity was assessed
as above described for pH stability experiments using casein-BODIPY-
FL and α-chymotrypsin or elastase (0.965 μM) as model proteases.
Far-UV circular dichroism (CD) spectra of U-Omp19 under different
pHs and temperatures were conducted (see supp. Materials and
methods).
To further study the protease inhibitory mechanism of U-Omp19,
the kinetic of trypsin, α-chymotrypsin and pancreatic elastase inhibi-
tion was performed (see supp. Materials and methods).
To evaluate if U-Omp19 inhibits proteolytic activity of stomach and
intestine extracts, stomach or intestine extracts from mice were pre-
incubatedwith buffer, different amounts of U-Omp19, Inhibitor cocktail
or BSA as negative control. Then, the mixtures were incubated with ca-
sein BODIPY-FL for 1 h or with OVADQ (quenched protein that releases
ﬂuorescence upon digestion) for 4 h and the ﬂuorescence increment
was determined.
To study protease inhibitor activity in vivoBALB/cmicewere orally—
intragastrically (i.g.) — administered with casein-BODIPY alone
(100 μg), plus U-Omp19 (150 μg) or aprotinin (1 μg). Stomachswere re-
moved 15 min and 1 h after oral delivery and extracts of the organs
were obtained. Afterwards Ag digestion was determined by ﬂuores-
cence emission. The dose of aprotinin used in this work was chosen be-
cause it did not produce adverse effects on treated animals and also
induced proteolysis inhibition of the antigen similar to U-Omp19
(data presented in this manuscript and not shown).
To study Ag fate after delivery BALB/c mice were i.g. administered
with PBS, OVA-FITC (100 μg) alone or OVAFITC (100 μg) plus U-
Omp19 (150 μg). Stomachs and small intestines were removed 90 min
after oral delivery and extracts of the organs were obtained. Afterwards
Ag presence was determined by ﬂuorescence emission.
2.5. Determination of Ag fate and proteolysis in vivo
To study Ag proteolysis in vivo Casein-BODIPY-FL or OVADQ
were used. To evaluate Ag fate and internalization in vivo OVA-
AlexaFluor647 or OVA-FITC were used. If Ags (OVA-FITC or casein-
BODIPY-FL) were used alone, mice were fed Ag (100 μg) plus i) buffer,
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control. To examine simultaneously Ag fate and degradation, mice
were fed both Ags simultaneously (100 μg OVA-AlexaFluor647 and
100 μg OVADQ) plus i) buffer, ii) U-Omp19 (300 μg), iii) CT (20 μg),
iv) aprotinin (2 μg) or buffer as control. At 2, 6, 12 and 18 h post admin-
istrationmicewere sacriﬁced and Peyer's Patches (PPs) andMesenteric
LymphNodes (MLNs)were aseptically removed. Single cell suspensions
were prepared [18], and washed twice in PBS solution to eliminate any
extracellular Ag, thus the ﬂuorescence determination was proportional
to Ag presence or proteolysis inside the cells. Total viable cells were
counted using Trypan Blue. Fluorescence intensity (FI) in arbitrary
units was determined in 1 × 106 cells. % of max. internalization of OVA
or % of OVA degradation was calculated as described in supplemental
material and methods.
To study cell subtypes involved in Ag internalization and processing,
cells were stained with ﬂuorochrome conjugated antibodies: anti-
CD11c, anti-CD8α, anti-CD11b and anti-MHC-II or isotype controls
and analyzed by ﬂow cytometry using FACSAriaII and FlowJo software
(Tree Star, OR).2.6. Immunizations
BALB/cmicewere orally immunized as described for other adjuvants
[19,20] on days 1, 2, 3, 8, 9 and 10with OVA (100 μg), OVA+U-Omp19
(150 μg), OVA + CT (10 μg) or OVA + aprotinin (1 μg). C57BL/6 mice
were immunized on days 0, 7 and 14. Onemonth after the last immuni-
zation mice were sacriﬁced to study immune responses.2.7. Determination of T helper immune responses
Spleen, PPs and MLNs single cell suspensions from immunized mice
were cultured in duplicates at 4 × 106 cells/ml in RPMI 1640
supplemented with 10% FCS (Life Technologies), sodium pyruvate
(1 mM), L-glutamine (2 mM), penicillin 100 U/ml, and streptomycin
(100 mg/ml) (complete medium) and stimulated with OVA, or com-
plete medium alone. After 72 h or 5 days of incubation at 37 °C in a hu-
midiﬁed atmosphere (5% CO2) cell culture supernatants were collected.
IFN-γ, IL-4, IL-10 and IL-17were determined by ELISA (Pharmingen and
R&D systems).2.8. Intracellular IFN-γ determination
Splenocytes from immunizedmicewere cultured (4 × 106 cells/well)
in presence of completemedium (supplementedwith IL-2) or Ag stimuli
(IL-2 plus OVA — 500 μg/ml, A20JOVA mitomicyn-treated cells as a
source of APCs (25:1) and OVA323 peptide) for 18 h. Next, brefeldin AFig. 1. (A) U-Omp19 presents sequence identity with other bacterial protease inhibitors of the
belonging to the inh protease inhibitor family: Pseudomonas aeruginosa Alkaline protease
chrysanthemi protease inhibitor P18958. Similar residues are colored as the most conserved
(see Supplementarymaterials andmethods). (B) Superposition of known andmodeled structur
PDB 1SMP) or Pseudomonas aeruginosa Alkaline protease inhibitor (green, PDB 1JIW) with Bru
Omp19 is a protease inhibitor. Protease inhibitor activity was determined using casein BODIPY
Pepsin, elastase, trypsin,α-chymotrypsin, carboxypeptidase A and Bwere pre-incubated in the
Omp19— 1:1, 1:5, 1:10 and 1:50 only with pepsin) or without U-Omp19 (1:0). A mammalian
controls at 1:10M ratio. Then, were incubated with 1 μg/ml casein BODIPY-FL for 1 h. Inhibitor
dition 1:0.★P b 0.05, ★★P b 0.01, ★★★P b 0.001 vs 1:0 condition. U-Omp19 is stable at different pH
(dotted line), pH 5 (dashed line) and pH 7.5 6M guanidinium chloride (GdmCl) (dashed and do
50, 60, 70, 80 and 90 °C (gray scaled full lines) and then back from90 to 20 °C (black dashed line
line). (F) U-Omp19 activity after exposure to different pH. U-Omp19was pre-incubated at room
forα-chymotrypsin. Residual inhibitor activity was assessed as in (C) using α-chymotrypsin as
activity is expressed as percentage of protease activity remainingwhen compared to condition−
Omp19 was pre-incubated at 25–100 °C for 1 h and subsequently adjusted to room temperatu
model proteases. Inhibitor activity is expressed as percentage of protease activity remaining w
and are representative of three independent experiments.was added for 5 h more to the samples. After that, cells were treated
and analyzed as described previously [13].
2.9. Determination of Ab responses
BALB/c micewere orally immunized as described on days 1, 2, 3, 8, 9
and 10 with CT (10 μg) or CT + U-Omp19 (10 + 150 μg). Same immu-
nization schedule was used when Shiga toxin (ST) was selected as Ag.
Other groups of mice were orally immunized with heat killed extract
from Salmonella-HKS (60 μg) or HKS + U-Omp19 (60 + 150 μg) on
days 0, 7 and 14. Feces and sera were obtained as described previously
[21] 2 weeks after last immunization to study Ag-speciﬁc- or U-
Omp19-speciﬁc IgA or IgG responses. Cut-off values for the ELISA assays
were calculated as themean speciﬁc OD plus 3 SD from 20 sera or feces
from non-immunized mice. Sera or feces titers were established as the
reciprocal of the last dilution yielding an OD higher than the cut-off.
2.10. Pathogen challenge assays
C3H/HeN mice were orally immunized on days 1, 2, 3, 8, 9 and 10
with PBS, puriﬁed recombinant E. coli GRA4 (30 μg), GRA4 + U-
Omp19 (100 μg) or GRA4+ CT (10 μg). Twoweeks after the last immu-
nization, some mice per group were injected intradermally in one
footpad with 20 μg of Ag (GRA4) and in the contralateral footpad with
an equal volume of saline. Footpad thickness was measured 72 h later
using a digital caliper with a precision of 0.01 mm, and the mean
increase in footpad thickness (mm) was calculated as: (footpad thick-
ness) Ag− (footpad thickness) saline. Threeweeks after last immuniza-
tion other mice were orally infected with 20 T. gondii tissue cysts of the
ME49 strain. Serum samples were obtained 8 days post challenge and
the activity of aspartate aminotransferase (AST), lactate dehydrogenase
(LDH), and alanine aminotransferase (ALT) were measured as an indi-
cation of liver damage [22] (Wiener Lab., Argentina). One month after
challenge, mice were sacriﬁced and their brains removed and homoge-
nized to determine the mean number of cysts per brain by observation
under optical microscope as described [23].
2.11. Statistical analysis
Statistical analysis and plotting were performed using GraphPad
Prism 4 software (GraphPad, San Diego, CA). In experiments with
more than 2 groups, data were analyzed using one-way ANOVA with
Bonferroni's post-test. If necessary, a logarithmic transformation was
applied prior to the analysis to obtain data with a normal distribution.
In experiments with 2 groups, Unpaired T Test was used. A P value
less than 0.05 was considered signiﬁcant. When bars are plotted results
are expressed as mean ± SEM for each group.inh family. Sequence alignment between B. abortus U-Omp19 and representative proteins
inhibitor (APRin) Q03026, Serratia marcescens protease inhibitor Q54478 and Erwinia
ones (according to BLOSUM62). Average BLOSUM62 score: Max: 3.0, Mid: 1.5, Low: 0.5.
es. Superposition of the three-dimensional structures of Erwinia chrysanthemi Inh (orange,
cella U-Omp19 (purple, homology model obtained with the SWISS MODEL server). (C) U-
-FL assay kit in which the increment in ﬂuorescence is proportional to proteolytic activity.
optimal buffer for each enzyme for 1 h at differentmolar ratioswith U-Omp19 (enzyme:U-
protease inhibitor cocktail was used as positive control and BSA and U-Omp16 as negative
activity is expressed as percentage of protease activity remaining when compared to con-
and temperature conditions. (D) Far-UV CD spectra of U-Omp19 at pH 7.5 (full line), pH 2
tted line). (E) Far-UV CD spectra of U-Omp19weremeasured at 20 (black full line), 30, 40,
). The spectrumof denatured protein in buffer containing 6MGdmCl is also shown (dotted
temperature for 1 h at different pH (2, 5, 7.5 and 8) and then adjusted to the optimumpH
model protease in a 1:10M ratio (protease:U-Omp19) or without inhibitor (−). Inhibitor
. (★★★P b 0.001 vs−). (G) U-Omp19 activity after incubation at different temperatures. U-
re. Residual inhibitor activity was assessed as in (F) using α-chymotrypsin or elastase as
hen compared to condition−. (★★★P b 0.001 vs−). Results are shown as mean ± SEM
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3.1. The protein moiety of B. abortus Omp19 (U-Omp19) is a protease
inhibitor
BLAST, Pfam and MEROPS sequence analysis report that U-Omp19
has signiﬁcant sequence identity with other bacterial protease inhibi-
tors, particularly with those representatives of inh protease inhibitor
family (family I38, clan IK): Pseudomonas aeruginosa protease inhibitor
(APRin), Serratia marcescens protease inhibitor and E. chrysanthemi pro-
tease inhibitor (Inh) [15,16] (Fig. 1A and supp. Materials andmethods).
Superposition of the known three-dimensional structures of Inh or
APRin with the homology model of Brucella U-Omp19 (obtained with
the SWISS MODEL server [24]) were performed. U-Omp19's beta barrel
core is predicted to be structurally similar to Inh and APRin (Fig. 1B).
Then, the ability of U-Omp19 to inhibit gastrointestinal proteases
was studied for the ﬁrst time. U-Omp19 is a protease inhibitor since it
was able to inhibit in vitro the activity of proteases present in the stom-
ach (pepsin, P b 0.001) and proteases secreted from the pancreas to the
intestine (elastase, trypsin and α-chymotrypsin, P b 0.001). Also it par-
tially inhibited the activity of carboxypeptidase B (P b 0.01) but could
not inhibit carboxypeptidase A (Fig. 1C). Bovine Serum Albumin (BSA)
and U-Omp16 from Brucella (a Brucella Omp with a molecular weight
very similar to U-Omp19) did not inhibit the enzymatic activity of any
of the proteases tested when used in a similar molar ratio to U-
Omp19, further indicating the speciﬁcity of the reaction assayed
(Fig. 1C).
These assays were performed under the optimal pHs of each prote-
ase. Of note, U-Omp19 inhibited in vitro pepsin activity at pH 2 suggest-
ing that its structure is stable at this low pH present at the stomach. To
conﬁrm this, Far-UV circular dichroism (CD) spectra of U-Omp19 under
different pHs and temperatures were conducted, which indicated that
U-Omp19 did not suffer any evident structural change under pH 2, 5
or 7.5. A control performed with U-Omp19 in a buffer containing 6 M
guanidinium chloride showed the loss of CD signal between 210 and
240 nm expected for a denatured U-Omp19. Moreover, the thermal de-
naturation experiment showed no signiﬁcant denaturation as CD signal
between 210 and 235 nmwas still present after heating U-Omp19 to
90 °C (Fig. 1D–E). Consequently U-Omp19 retained its full protease
inhibitor activity when previously exposed to a broad pH (2–8) or
temperature (25–100 °C) range (P b 0.001) (Fig. 1F–G).
To further study the protease inhibitory mechanism of U-Omp19,
the kinetic of trypsin (Fig. 2A),α-chymotrypsin (Fig. 2B) and pancreatic
elastase (Fig. 2C) inhibition was studied (see Supp. Materials and
methods). Lineweaver–Burk and Dixon plots indicated that U-Omp19
inhibited the three serine proteases in a mixed noncompetitive manner
[25] (Fig. 2 left andmiddle panels), indicating that U-Omp19binds both,
the free proteases and the protease-substrate binary complexes. As U-
Omp19 does not compete with the substrates for binding to the free
proteases; it binds these serine proteases at a site distinct from the ac-
tive site. Global nonlinear ﬁt of data was used to estimate Ki and alpha
values. Determined Ki values (Mean; Std Error) were: (77.39 μM;
21.23) for Trypsin, (55.75 μM; 10.40) for α-Chymotrypsin and
(128.0 μM; 41.6) for pancreatic Elastase. For the three proteases the es-
timated values of alpha were between 1.8 and 3.4, indicating that U-
Omp19 bound both, the free proteases and the protease-substrate bina-
ry complexes, but with different afﬁnities (Fig. 2, right panels). Together
these results indicate that U-Omp19 exhibits a mixed noncompetitive
type inhibitory activity against main gut proteases (trypsin, α-
chymotrypsin and elastase) with Ki values in the μM range.
As the in vivo content and proportion of proteases in the gastrointes-
tinal tract is diverse in the different organs, the ability of U-Omp19 to in-
hibit proteases activity in stomach or intestine extracts was studied. U-
Omp19was able to partially (40–60%) inhibit in vitro the protease activity
of stomach (P b 0.001) or intestine (P b 0.001) extracts from mice using
two different substrates: casein and ovalbumin (OVA) (Fig. 3A–B). Asexpected, BSA did not inhibit the proteolytic activity of stomach or intes-
tine extracts in vitrowhereas a protease inhibitor cocktail did (Fig. 3A–B).
To study in vivo the biological activity of U-Omp19 animals were i.g.
administered, on one occasion, with casein-BODIPY (model Ag which
exposes its dyes and ﬂuoresces when digested) alone, plus U-Omp19
or plus aprotinin. Stomachs were removed 15 min and 1 h (h) later
and casein digestion was determined. Oral co-administration of U-
Omp19 prevented Ag degradation in vivo (~50%) in the stomach (P b
0.001) ofmice at 15min (Fig. 3C). The proteolysis inhibitionwas a slight
lesser than that obtained when aprotinin was used. At 60 min there is
still signiﬁcant reduction (P b 0.05) in Ag digestion (~25%) at the stom-
ach (Fig. 3C). Moreover, using OVA-FITC as amodel Ag in vivo there was
an increase, at 90min post-delivery, in the amount of Ag at the stomach
(slight but not signiﬁcant) and intestine (P b 0.05) when it was co-
administered orally with U-Omp19 (Fig. 3D).
Taken together these and above results indicate that U-Omp19 is a
pH- and temperature-resistant, protease inhibitor of stomach and gut
proteases.
3.2. Oral U-Omp19 co-administration limits proteolysis of the Ag within
cells from Peyer's Patches and Mesenteric Lymph Nodes, increasing the
amount of Ag at these sites
To induce an adaptive immune response Ags must reach inductive
sites (PPs andMLNs) of the gastrointestinal immune system. Oral deliv-
ery of U-Omp19 increased the amount of the co-administeredmodel Ag
OVA-AlexaFluor647 (Figs. 4A and S1A ﬂuorescence arbitrary units
shown) or OVA-FITC (Fig. S2A) inside cells from PPs at 2, 6 and 12 h
(P b 0.001, P b 0.001, P b 0.01 vs OVA delivered alone) and in cells
from MLNs at 6, 12 and at 18 h post administration (P b 0.05, P b 0.01,
P b 0.001). Neither CT nor aprotinin -a known eukaryotic serine prote-
ase inhibitor- co-administrationwas as efﬁcient as U-Omp19 at increas-
ing the amount of intracellular Ag at the inductive sites.
Digestive enzymes break down large polypeptides into non-
immunogenic di- and tri-peptides, too small to bind tomajor histocom-
patibility complex (MHC) molecules [26]. Accordingly with the inhibi-
tion of the stomach and gut proteases, U-Omp19 co-administered by
the oral route decreased the amount of digested Ag (OVADQ or
casein-BODIPY) within cells from PPs at 2, 6 and 12 h (P b 0.01, P b
0.001, P b 0.01) and in MLNs at 6, 12 and 18 h post-vaccination (P b
0.001, P b 0.01, P b 0.01) (Figs. 4B, S1B and S2B ﬂuorescence arbitrary
units shown). In contrast, CT co-administration did not reduce the
amount of degraded Ag in the inductive sites. Altogether these results
indicate that U-Omp19 co-administration by the oral route can limit
the susceptibility of the Ag to proteolysis in vivo at the gastrointestinal
tract, increasing the half-life of the Agwithin cells of the immune induc-
tive sites: PPs and MLNs.
3.3. U-Omp19 induces the recruitment, activation and increases
the amount of Ag within monocytes and DCs at PPs and MLNs after oral
co-administration
Inducing an appropriate inﬂammatory response is crucial to drive an
efﬁcient adaptive immune response. In relation to this, single oral ad-
ministration of Ag plus U-Omp19 induced DCs (CD11c+) recruitment
to PPs (P b 0.01) as well as monocytes (CD11b+ CD11c−) and CD8α+
DCs (CD11c+ CD8α+) recruitment to MLNs (P b 0.05 at 4 h and P b
0.01 at 18 h post delivery) (Fig. S3). CT co-administration or aprotinin
induced lower monocyte- and DC-recruitment (Fig. S3). Moreover,
only U-Omp19 was able to induce the recruitment of a particular DC
subtype: CD11c+ CD8α+ DCs, known to stimulate Th1 responses and
Ag crosspresentation to CD8+ T cells [27] (Fig. S3).
Worth mentioning, U-Omp19 co-administered by the oral route in-
creased the amount of Agwithinmonocytes and CD11c+ CD8α+DCs at
PPs and MLNs (Fig. 4C). In agreement to the results shown in Figs. 1–3,
the amount of digested Ag inside monocytes and CD11c+ CD8α+ DCs
Fig. 2. Kinetics of U-Omp19's inhibition of (A) trypsin, (B)α-chymotrypsin and (C) pancreatic elastase. Samples of the speciﬁed enzyme preparations were treatedwith different concen-
trations of U-Omp19 before addition of the indicated speciﬁc substrate concentrations. Proteolytic activity wasmeasured as the increment in ﬂuorescence units of samples. Linear regres-
sions of ﬂuorescent units versus time (s)were used to calculate initial velocities (V0) for each substrate concentration [S] and inhibitor concentration [U-Omp19] combination sample. Data
were transformed into Lineweaver–Burk plots (1/V0 vs. 1/[S]) (left panels) and Dixon plots (1/V0 vs. [U-Omp19]) (middle panels). Best-ﬁt lines were generated by linear regression anal-
ysis. Global nonlinear ﬁt of data were used to calculate Ki and alpha values (right panels). Each panel is representative of at least three independent experiments.
23A.E. Ibañez et al. / Journal of Controlled Release 220 (2015) 18–28from PPs partially decreased after oral U-Omp19 co-administration
(Fig. S4). Furthermore, U-Omp19 oral administration induced in vivo
the activation of DCs, as CD8α+ CD11b− CD11c+MHCII+ DCs recruited
to MLNs showed up-regulated expression of co-stimulatory molecules
(CD80, CD40 and CD86) (Fig. 4D and supplementary materials and
methods).
These results indicate that U-Omp19 induces the recruitment and
activation of APCs to mucosal inductive sites and can increase Ag intra-
cellular half-life in APCs.
3.4. Oral co-administration of U-Omp19 increases mucosal and systemic T
lymphocyte adaptive immune responses
To study if oral delivery of OVA in the presence of U-Omp19 resulted
in a signiﬁcantly increased adaptive immune response, BALB/c mice
were orally immunized with OVA plus i) buffer, ii) U-Omp19, iii) CT or
iv) aprotinin. MLNs cells from OVA + U-Omp19 immunized mice pro-
duced signiﬁcant amounts of IFN-γ and IL-17 in response to OVA
(P b 0.05 vs OVA immunized mice, Fig. 5A). On the contrary, the same
cells did not produce IL-4 or IL-10 after OVA in vitro stimulation (data
not shown). Also, co-administration of OVA plus U-Omp19 induced
OVA-speciﬁc IFN-γ at the spleens (P b 0.05). A slight but not statistically
signiﬁcant OVA-speciﬁc IL-17 production was evidenced only in
the spleens of OVA + U-Omp19 immunized animals (Fig. 5A). OVA-speciﬁc IFN-γ producing CD4+ and CD8+ T cells were found in animals
immunized with OVA plus U-Omp19 (Fig. 5B). In contrast, CT or
aprotinin co-administration did not induce OVA-speciﬁc IFN-γ produc-
ing CD4+ T or CD8+ T cells nor IFN-γ or IL-17 secretion from stimulated
MLNs and splenocytes (Fig. 5A–B). Similarly, animals immunized with
OVA + U-Omp19 showed OVA-speciﬁc T cell responses in vivo (DTH
assay) (P b 0.05) while animals immunized with OVA or OVA + CT
did not (Fig. S5A). Also, oral co-administration of U-Omp19 or aprotinin
induced a slight but not signiﬁcant increase in anti-OVA IgA in feces,
while CT + OVA did it (P b 0.05) (Fig. S5B). Important, anti-U-Omp19
IgA or anti-U-Omp19 IgG was not detected in any immunized group
(Fig. S5B–C). U-Omp19 immunization alone did not elicit speciﬁc adap-
tive immune responses to OVA (Figs. S5A and S9).
The α4β7 integrin is critical for lymphocyte homing to the small in-
testine [28]. Oral delivery of OVA with U-Omp19 resulted in a signiﬁ-
cantly increased population of MLN CD4+ and CD8+ T cells with up-
regulated α4β7 integrin expression 1 month after immunization in
BALB/c mice. A similar degree of up-regulation was observed when
OVA was co-administered with CT (Fig. S5D).
To study adaptive immune responses under a different genetic
background, C57BL/6 mice were orally immunized with OVA,
OVA + U-Omp19 or OVA + CT. One month later, OVA speciﬁc-Th1
and OVA-speciﬁc IFN-γ producing CD4+ T and CD8+ T cells were evi-
denced at the mucosal as well as systemic level, if U-Omp19 was co-
Fig. 4.U-Omp19 oral co-administrationwith anAg limits Ag proteolysis and increases the amount of Agwithin cells at PPs andMLNs.Mice (n=3/group)were i.g. administered oncewith
amixture of OVAAlexa Fluor-647 (OVAAF647) andOVADQplus i) buffer, ii) U-Omp19, iii) cholera toxin (CT), iv) aprotinin or buffer alone as a control. At different timepoints post delivery
PP orMLN cell suspensionswere obtained andwashedwith PBS to eliminate extracellular Ag and Agpresence or proteolysiswas determined in 1× 106 cells by detection of OVAAlexa 647
(A) or OVADQ (B) ﬂuorescence respectively. Fluorescence increase is proportional to the amount of Ag in the case of OVAAF647 while it is proportional to Ag degradation in the case of
OVADQ. Results are expressed as % ofmax. internalization of OVA or % of OVA degradation (mean±SEM). Representative of three independent experiments. (C) Oral delivery of U-Omp19
increases the amount of Agwithin APCs in vivo. Ag presencewas determined by ﬂow cytometry in CD11c+, CD11c+ CD8α+ and CD11c− CD11b+ cells at PPs andMLNs 4 h after single oral
delivery of OVAFITC plus i) buffer, ii) U-Omp19, iii) CT or iv) aprotinin. Results are presented as representative histograms obtained for each group (n=3/group) and are representative of
two different experiments. (D) U-Omp19 induces activation of APCs in vivo. Flow cytometric analysis of CD80, CD40 and CD86 expression byMLN CD11c+MHC-II+ and CD11c+MHC-II+
CD8α+DCs after single oral delivery of i) OVA or ii) OVA+U-Omp19 at 18 h post-administration. Results are presented as representative histograms obtained for each group (n=3/group)
and are representative of two different experiments.
Fig. 3. U-Omp19 inhibits proteolytic activity of stomach and intestine extracts. Stomach and Intestine extracts frommice were pre-incubated with buffer (−), different amounts of U-Omp19
(3,6 μg; 18 μg or 36 μg/well), Inhibitor cocktail or BSA (36 μg/well) as negative control. Then, themixtures were incubatedwith casein BODIPY-FL for 1 h (A) orwith OVADQ for 4 h (B) and the
ﬂuorescence incrementwas determined. Results are presented as percentage of Casein orOVAdigestion compared to the conditionwithout inhibitor:−. (★P b 0.05,★★P b 0.01 and★★★P b 0.001
vs−). U-Omp19 partially inhibits Ag digestion in vivo. (C) Animalswere fedwith buffer, casein BODIPY-FL alone, casein BODIPY-FL plus U-Omp19 or casein BODIPY-FL plus aprotinin. Stomachs
were removed 15 min and 1 h after oral delivery and Ag digestion was determined. Results are presented as percentage of Casein digestion compared to the group fed with casein BODIPY-FL
alone. (★P b 0.05, ★★P b 0.01 and ★★★P b 0.001 vs−). (D) Animalswere i.g. deliveredwith buffer, OVAFITC alone orOVAFITC plusU-Omp19. Stomachs and small intestineswere removed90min
after oral delivery andAg fatewas determined. Results are presented as percentage of OVA-FITC compared tomaximum ﬂuorescence intensitymeasured. Results are shown asmean±SEM for
each group (n= 4) and are representative of three independent experiments. (★P b 0.05 vs casein or OVA alone group).
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Fig. 5.Oral immunization of U-Omp19with Ag increasesmucosal and systemic Ag-speciﬁc Th1–Th17 immune responses in BALB/c. Cytokine (IFN-γ and IL-17) production determined by ELISA
on supernatants harvested 5 days after stimulation of (A)MLN and spleen cellswith OVA or completemedium. Cells were obtained 3weeks after the last boost of animals (n=6/group) orally
immunizedwith OVA, OVA+U-Omp19, OVA+CT or OVA+ aprotinin. Results are shown asmean± SEM for each group and are representative of 3 independent experiments. (★P b 0.05 vs
OVAgroup). (B) Spleen cells from immunizedmicewere stimulated in vitrowith OVA for 23 h, last 5 h cellswere treatedwith brefeldin A. Then, cells were stainedwith speciﬁc antibodies anti-
CD4, anti-CD8,ﬁxed, permeabilized and stained intracellularlywith anti-IFN-γ forﬂow cytometry analysis. Results are presented as percentage of IFN-γ producing T cells and are representative
of 3 independent experiments.
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(Fig. S6). These results indicate that U-Omp19 has a similar immune ad-
juvant effect in BALB/c and C57BL/6 mice.
Together these results indicate that oral co-administration of this
bacterial protease inhibitor with Ag increases mucosal and systemic
Ag-speciﬁc Th1, Th17 and CD8+ T cell immune responses.3.5. U-Omp19 co-administered orally with bacterial Ags increases Ag-
speciﬁc mucosal IgA and systemic IgG responses
OVA-speciﬁc antibody (Ab) mucosal responses were difﬁcult to
achieve using U-Omp19 (Fig. S5B–C). Thus, to test U-Omp19's capacity
to elicit Ab responses we decided to use other Ags, such as Shiga Toxin
(Stx2) from E. coli, CT from Vibrio cholera or a heat killed extract from
Salmonella typhimurium (HKS). There was a signiﬁcant increase
(P b 0.01) in anti-ST IgA in feces when ST was orally co-administered
with U-Omp19 (Fig. 6A and supplementary material and methods).
Serum anti-ST IgG responses were not induced in any immunized
group (Fig. S7A). Oral co-administration of U-Omp19with CT (as Ag) in-
duced increased (P b 0.05 vs CT alone) anti-CT IgA in feces and IgG in
sera (Fig. 6B). Also, U-Omp19 oral co-administration with HKS in-
creased anti-HKS fecal IgA and serum IgG compared with oral deliveryFig. 6. U-Omp19 co-administered orally with bacterial Ags can increase mucosal Ag-speciﬁc Ig
alone (CT, HKS or ST) or the Ag+ U-Omp19. (A) ST-, (B) CT- and (C) HKS-speciﬁc IgG and IgA w
are expressed as mean Ab titers or OD 492 nm± SEM for each group (n= 5–6/group) and ar
group).of HKS alone (Fig. 6C). Anti-U-Omp19 serum IgG or fecal IgA were not
detected in any immunized group (Fig. S7B–C).
Altogether these results indicate that U-Omp19 co-administered
orally with pathogen-derived Ags can increase Ag-speciﬁc mucosal IgA
and systemic IgG responses.3.6. U-Omp19 in an oral vaccine formulation induces protection against
oral challenge with a virulent parasite
Besides and considering that Toxoplasma gondii is able to infect the
host through the gutmucosa and Th1 responses are known to be impor-
tant in protection [29], these prompted us to study T. gondii infection
model for vaccination using U-Omp19. Thus, the efﬁcacy of oral immu-
nization with a recombinant protein GRA4 plus U-Omp19 was evaluat-
ed. C3H/HeN mice were orally immunized with i) PBS, ii) GRA4, iii)
GRA4 + U-Omp19 or iv) GRA4 + CT. Three weeks after the last boost,
mice were challenged orally with Me49 tissue cysts and individual par-
asite levels were assessed 1 month later. An important decrease in the
brain cyst burden (P b 0.05) together with a reduction in serum of
liver damage associated enzymes (AST, LDH and ALT) and an increase
(P b 0.05) in GRA4-speciﬁc IgA and DTH was observed in GRA4 + U-
Omp19 immunizedmice as compared to the control groups (Fig. 7A–C).A and serum Ag-speciﬁc IgG responses. BALB/c mice were orally immunized with PBS, Ag
ere determined in sera and in feces respectively 2 weeks after last immunization. Results
e representative of three independent experiments (★P b 0.05 and ★★P b 0.01 vs Ag alone
Fig. 7. U-Omp19 in an oral vaccine formulation reduces parasite levels after oral challenge with Toxoplasma gondii. C3H/HeN mice were orally immunized with PBS, GRA4, GRA4 + U-
Omp19 or GRA4+ CT and orally infected with T. gondii tissue cysts three weeks later. (A) Mean number of cysts per brain were counted 1 month after challenge. Activity of the speciﬁed
enzymes (AST, LDH and ALT)wasmeasured in serum obtained 8 days post challenge. (B) GRA4 speciﬁc IgA Abs in feces were determined 3weeks after the last immunization. Results are
shown asmean OD at 492 nm±SEM for each group (C) DTH response to GRA4 assessed twoweeks after the last immunization. Results are shown asmean increment in the hind footpad
between right and left foot ±SEM for each group (n/group = 6–8), measured 72 h later. (★P b 0.05 vs PBS or GRA4 group).
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stituent of oral vaccine formulations against infectious diseases.
4. Conclusions and discussion
There is no vaccine that is more amenable to mass immunization in
ﬁeld settings than oral vaccine. Yet, there is a relative paucity of oral vac-
cines in currentmedical practice. The greatest threat to peptide andpro-
tein oral administration lies in the small intestine, which contains large
quantities of peptidases. For example, luminal digestion in the duode-
num by trypsin and chymotrypsin can convert almost half of the
ingested protein to trichloroacetic acid-soluble material within
10 min, 60–70% of which is in the form of small peptides with 2–6
amino acids that cannot bind MHC molecules [26].
As demonstrated in this work, we have completed proof of concept
studies that indicate that a Brucella spp. protein would be a useful com-
ponent in an oral vaccine formulation because: i) it bypasses the hostile
environment of the gastrointestinal tract inhibiting stomach and gut
proteases and consequently increases the half-life of co-administered
Ags at the inductive sites: PPs andMLNs while ii) it induces the recruit-
ment of APCs, activation and Ag internalization. Besides, it reduces the
amount of digested Ag within APCs at inductive sites. Consequently,
mucosal as well as systemic Ag-speciﬁc immune responses, Abs, Th1,
Th17 and CD8+ T cells are enhanced if U-Omp19 is orally co-
administered with the Ag.
The inhibition of proteolysis and induction of immune responses has
also been demonstrated using BALB/c, C57BL/6 (Fig. S6 and Supplemen-
tarymaterial) or C3H/HeNmice further indicating that U-Omp19 can be
used under different genetic backgrounds. Moreover, in this work U-
Omp19's usefulness was evaluated using model Ags such us OVA and
casein as well as bacterial and parasite derived Ags.
As U-Omp19 possesses the capability of partially inhibiting the de-
struction of the Ag, less Ag would be needed to induce protection,
which could lower vaccine costs. Interestingly, this protease inhibitor
is pH and thermally stable; these are important attributes that will
allow it to work at the low pH from the stomach and its use in vaccines
avoiding cold chain.We believe that if U-Omp19would not be pH stable
nor be able to inhibit stomach and gut proteases immune properties cannever been seen. This would explainwhy at presentmostmucosal adju-
vants are given intranasal and not oral to avoid their digestion before
reaching immune cells.
Being U-Omp19 a protein, the observed effect on gastrointestinal
proteases should be short term and reversible because U-Omp19
-when present in the gut- will be ﬁnally digested by the proteases
newly secreted from the pancreas to the intestine. In fact, we have dem-
onstrated that U-Omp19 effect on in vivo inhibition of proteolysis is
transient. Moreover, the amount of in vivo inhibition is not total,
allowing digestion, whichwould lower the chances of potential adverse
effects of U-Omp19 in vaccine formulations. Of note, there were no vis-
ible adverse effects in mice or histopathological changes in PPs, MLNs
and intestines from U-Omp19 orally immunized mice (Fig. S8). Worth
mentioning, antibody responses against U-Omp19 were not detected
in any immunized group. This was reported in our previous work
using U-Omp19 alone as Ag [14] and in the present work where U-
Omp19 was orally co-administered with the Ag. This is of great impor-
tance because it was described for other adjuvants and delivery systems
that antibody responses against their selfmay inhibit subsequent utility.
Hence these results would support repeated use of U-Omp19 contained
in different vaccine formulations without anticipating this problem.
In this work U-Omp19's mechanism of action in vitro on main gut
proteases was characterized for the ﬁrst time and results indicated
that U-Omp19 inhibits trypsin, chymotripsin and pancreatic elastase
by a mixed non-competitive mechanism of inhibition and with a Ki in
the μM range. Representative proteins belonging to inh protease inhib-
itor family as is U-Omp19 from Brucella spp. are: P. aeruginosa Alkaline
protease inhibitor (APRin), S. marcescens protease inhibitor (SmaPI)
and E. chrysanthemi protease inhibitor (Inh). It is probable that these in-
hibitors protect bacteria from proteolysis during export of self proteases
[30]. Until present there are few studies on these types of protease in-
hibitors (family inh I38), and all of them were shown to inhibit their
cognate — self — or heterologous bacterial proteases [15,30]. However,
while belonging to other family of protease inhibitors there is a
known broad spectrum protease inhibitor from bacteria— from the en-
tomopathogenic bacterium Photorhabdus luminescens— that can inhibit
also mammalian proteases like trypsin and elastase [17] as is the case
for U-Omp19 from Brucella spp. Despite we have demonstrated that
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from large animals like pigs (Fig. S10) we believe that new systems in-
cludingmicro-, nanoparticles and enteric capsules may have signiﬁcant
potential to increase U-Omp19 capacity to work in larger animals using
advanced combined formulations in the future.
Although there are studies that postulate the usefulness of mamma-
lian protease inhibitors like aprotinin for the co-administration of oral
drugs [31,32] and before oral immunization [33] to our knowledge
there are no published reports describing the use of a bacterial protease
inhibitor in oral vaccine formulations. Until present most studies on the
immunomodulatory properties of protease inhibitors were conducted
on eukaryotic protease inhibitors [34–36] and some viral as well as ﬁlar-
ial nematodes protease inhibitors [35,37] that were found to be immu-
noregulatory and anti-inﬂammatory. For example, a serine leucocyte
proteinase inhibitor targets monocytes, which in turn inhibit CD4+ T
cell proliferation and Th1 cytokine secretion [36,38]. In fact, our results
demonstrated that a eukaryotic protease inhibitor like aprotinin can
limit gastrointestinal digestion of the co-administered Ag but cannot in-
crease immune responses, this last particularity is important for its appli-
cation on oral delivery of drugs where immune reactions must be
avoided. In contrast, a bacterial protease inhibitor inhibits digestion
and increases mucosal and systemic Abs, Th1, Th17 and CD8+ immune
responses.
The natural route of infection and theneed for a Th1-biased response
[29] make T. gondii strong candidate for oral vaccination with the
novel adjuvant U-Omp19. Consequently, in this work we conﬁrmed
U-Omp19's usefulness in an oral subunit vaccine formulation against
oral T. gondii infection. Nowadays, most used and approved adjuvants
are associated with the induction of Th2 and humoral responses [39].
As U-Omp19 induces Abs, Th1, Th17 and CD8+ T cell mucosal immune
responses, the discovery of this novel type of molecules: protease
inhibitor/adjuvant lays the groundwork for new directions in mucosal
vaccine design against infectious diseases [3,40].
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